We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Less Invasive Breast Cancer Therapy Found Equally Effective

By HospiMedica International staff writers
Posted on 07 Oct 2010
Women with early stage breast cancer who underwent sentinel-lymph-node (SLN) resection had the same survival rates as women who had a more aggressive surgery to remove all of their axillary lymph nodes, according to new study.

Researchers participating in the U.S. More...
National Surgical Adjuvant Breast and Bowel Project (NSABP; Pittsburgh, PA, USA) randomized 5,611 women with invasive breast cancer in a controlled phase 3 trial at 80 centers in Canada and the United States between May 1, 1999, and Feb 29, 2004. The women were assigned to either SLN resection plus axillary-lymph-node dissection (ALND), or to SLN resection alone, with ALND performed only if the SLNs were found positive. The primary endpoint was overall survival. Outcome analyses were done in patients who were assessed as having pathologically negative sentinel nodes, and for whom follow-up data were available. All deaths, irrespective of cause, were included.

The results showed that 3,989 of the women had pathologically negative SLN. Of these, 309 deaths were reported in the SLN-negative patients with follow-up information: 140 of 1,975 patients in the SLN plus ALND group, and 169 of 2,011 in SLN alone group. Overall survival in both groups yielded an unadjusted hazard ratio (HR) of 1.20; 8-year estimates for overall survival were 91.8% in the SLN plus ALND group, and 90.3% in the SLN alone group. Treatment comparisons for disease-free survival yielded an unadjusted HR of 1.05, and 8-year estimates for disease-free survival were 82.4% in the first group and 81.5% in the second; 14 women in the SLN group had cancer return, compared to 8 of those who had the more aggressive surgery. The study was published early online on September 21, 2010, in the Lancet Oncology.

"Overall survival, disease-free survival, and regional control were statistically equivalent between groups,” concluded lead author professor David Krag, M.D., of the University of Vermont (Burlington, USA). "When the SLN is negative, SLN surgery alone with no further ALND is an appropriate, safe, and effective therapy for breast cancer patients with clinically negative lymph nodes.”

The sentinel lymph node is the hypothetical first lymph node or group of nodes reached by metastasizing cancer cells from a primary tumor. The concept of the sentinel lymph node is important because of the advent of the sentinel lymph node biopsy technique, also known as a sentinel node procedure, used in the staging of certain types of cancer to see if they have spread to any lymph nodes, since lymph node metastasis is one of the most important prognostic signs. It can also guide the surgeon to the appropriate therapy.

Related Links:

U.S. National Surgical Adjuvant Breast and Bowel Project
University of Vermont



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.